Cargando…

m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway

BACKGROUND: Gemcitabine resistance has brought great challenges to the treatment of pancreatic cancer. The N6-methyladenosine (m6A) mutation has been shown to have a significant regulatory role in chemosensitivity; however, it is not apparent whether gemcitabine resistance can be regulated by fat ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Kai, Zhou, Endi, Shi, Ting, Zhang, Siqing, Zhang, Jinfan, Zheng, Ziruo, Pan, Yuetian, Gao, Wentao, Yu, Yabin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464189/
https://www.ncbi.nlm.nih.gov/pubmed/37605223
http://dx.doi.org/10.1186/s13046-023-02792-0
_version_ 1785098411640356864
author Lin, Kai
Zhou, Endi
Shi, Ting
Zhang, Siqing
Zhang, Jinfan
Zheng, Ziruo
Pan, Yuetian
Gao, Wentao
Yu, Yabin
author_facet Lin, Kai
Zhou, Endi
Shi, Ting
Zhang, Siqing
Zhang, Jinfan
Zheng, Ziruo
Pan, Yuetian
Gao, Wentao
Yu, Yabin
author_sort Lin, Kai
collection PubMed
description BACKGROUND: Gemcitabine resistance has brought great challenges to the treatment of pancreatic cancer. The N6-methyladenosine (m6A) mutation has been shown to have a significant regulatory role in chemosensitivity; however, it is not apparent whether gemcitabine resistance can be regulated by fat mass and obesity-associated protein (FTO). METHODS: Cells with established gemcitabine resistance and tissues from pancreatic cancer patients were used to evaluate FTO expression. The biological mechanisms of the effects of FTO on gemcitabine resistant cells were investigated using CCK-8, colony formation assay, flow cytometry, and inhibitory concentration 50. Immunoprecipitation/mass spectrometry, MeRIP-seq, RNA sequencing and RIP assays, RNA stability, luciferase reporter, and RNA pull down assays were employed to examine the mechanism of FTO affecting gemcitabine resistant pancreatic cancer cells. RESULTS: The results revealed that FTO was substantially expressed in cells and tissues that were resistant to gemcitabine. Functionally, the gemcitabine resistance of pancreatic cancer could be enhanced by FTO, while its depletion inhibited the growth of gemcitabine resistant tumor cells in vivo. Immunoprecipitation/mass spectrometry showed that the FTO protein can be bound to USP7 and deubiquitinated by USP7, leading to the upregulation of FTO. At the same time, FTO knockdown significantly decreased the expression level of NEDD4 in an m6A-dependent manner. RNA pull down and RNA immunoprecipitation verified YTHDF2 as the reader of NEDD4, which promoted the chemoresistance of gemcitabine resistant cells. FTO knockdown markedly increased the PTEN expression level in an NEDD4-dependent manner and influenced the chemosensitivity to gemcitabine through the PI3K/AKT pathway in pancreatic cancer cells. CONCLUSION: In conclusion, we found that gemcitabine resistance in pancreatic cancer can be influenced by FTO that demethylates NEDD4 RNA in a m6A-dependent manner, which then influences the PTEN expression level and thereby affects the PI3K/AKT pathway. We also identified that the FTO level can be upregulated by USP7. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-023-02792-0.
format Online
Article
Text
id pubmed-10464189
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104641892023-08-30 m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway Lin, Kai Zhou, Endi Shi, Ting Zhang, Siqing Zhang, Jinfan Zheng, Ziruo Pan, Yuetian Gao, Wentao Yu, Yabin J Exp Clin Cancer Res Research BACKGROUND: Gemcitabine resistance has brought great challenges to the treatment of pancreatic cancer. The N6-methyladenosine (m6A) mutation has been shown to have a significant regulatory role in chemosensitivity; however, it is not apparent whether gemcitabine resistance can be regulated by fat mass and obesity-associated protein (FTO). METHODS: Cells with established gemcitabine resistance and tissues from pancreatic cancer patients were used to evaluate FTO expression. The biological mechanisms of the effects of FTO on gemcitabine resistant cells were investigated using CCK-8, colony formation assay, flow cytometry, and inhibitory concentration 50. Immunoprecipitation/mass spectrometry, MeRIP-seq, RNA sequencing and RIP assays, RNA stability, luciferase reporter, and RNA pull down assays were employed to examine the mechanism of FTO affecting gemcitabine resistant pancreatic cancer cells. RESULTS: The results revealed that FTO was substantially expressed in cells and tissues that were resistant to gemcitabine. Functionally, the gemcitabine resistance of pancreatic cancer could be enhanced by FTO, while its depletion inhibited the growth of gemcitabine resistant tumor cells in vivo. Immunoprecipitation/mass spectrometry showed that the FTO protein can be bound to USP7 and deubiquitinated by USP7, leading to the upregulation of FTO. At the same time, FTO knockdown significantly decreased the expression level of NEDD4 in an m6A-dependent manner. RNA pull down and RNA immunoprecipitation verified YTHDF2 as the reader of NEDD4, which promoted the chemoresistance of gemcitabine resistant cells. FTO knockdown markedly increased the PTEN expression level in an NEDD4-dependent manner and influenced the chemosensitivity to gemcitabine through the PI3K/AKT pathway in pancreatic cancer cells. CONCLUSION: In conclusion, we found that gemcitabine resistance in pancreatic cancer can be influenced by FTO that demethylates NEDD4 RNA in a m6A-dependent manner, which then influences the PTEN expression level and thereby affects the PI3K/AKT pathway. We also identified that the FTO level can be upregulated by USP7. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-023-02792-0. BioMed Central 2023-08-22 /pmc/articles/PMC10464189/ /pubmed/37605223 http://dx.doi.org/10.1186/s13046-023-02792-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Lin, Kai
Zhou, Endi
Shi, Ting
Zhang, Siqing
Zhang, Jinfan
Zheng, Ziruo
Pan, Yuetian
Gao, Wentao
Yu, Yabin
m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway
title m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway
title_full m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway
title_fullStr m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway
title_full_unstemmed m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway
title_short m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway
title_sort m6a eraser fto impairs gemcitabine resistance in pancreatic cancer through influencing nedd4 mrna stability by regulating the pten/pi3k/akt pathway
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464189/
https://www.ncbi.nlm.nih.gov/pubmed/37605223
http://dx.doi.org/10.1186/s13046-023-02792-0
work_keys_str_mv AT linkai m6aeraserftoimpairsgemcitabineresistanceinpancreaticcancerthroughinfluencingnedd4mrnastabilitybyregulatingtheptenpi3kaktpathway
AT zhouendi m6aeraserftoimpairsgemcitabineresistanceinpancreaticcancerthroughinfluencingnedd4mrnastabilitybyregulatingtheptenpi3kaktpathway
AT shiting m6aeraserftoimpairsgemcitabineresistanceinpancreaticcancerthroughinfluencingnedd4mrnastabilitybyregulatingtheptenpi3kaktpathway
AT zhangsiqing m6aeraserftoimpairsgemcitabineresistanceinpancreaticcancerthroughinfluencingnedd4mrnastabilitybyregulatingtheptenpi3kaktpathway
AT zhangjinfan m6aeraserftoimpairsgemcitabineresistanceinpancreaticcancerthroughinfluencingnedd4mrnastabilitybyregulatingtheptenpi3kaktpathway
AT zhengziruo m6aeraserftoimpairsgemcitabineresistanceinpancreaticcancerthroughinfluencingnedd4mrnastabilitybyregulatingtheptenpi3kaktpathway
AT panyuetian m6aeraserftoimpairsgemcitabineresistanceinpancreaticcancerthroughinfluencingnedd4mrnastabilitybyregulatingtheptenpi3kaktpathway
AT gaowentao m6aeraserftoimpairsgemcitabineresistanceinpancreaticcancerthroughinfluencingnedd4mrnastabilitybyregulatingtheptenpi3kaktpathway
AT yuyabin m6aeraserftoimpairsgemcitabineresistanceinpancreaticcancerthroughinfluencingnedd4mrnastabilitybyregulatingtheptenpi3kaktpathway